Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF.

Abstract

To evaluate the clinical effects of the administration of recombinant human granulocyte-stimulating factor (rhG-CSF) post chemotherapy for patients with advanced-staged intermediate-grade or high-grade non-Hodgkin's malignant lymphoma (NHL), we conducted this multicenter study and compared the responses between both the regimens, CHOP as a first-generation chemotherapy and ProMACE/CytaBOM as a third-generation chemotherapy, when combined with the rhG-CSF administration. In this multicenter study, where forty patients were registered, patients in both the CHOP and ProMACE/CytaBOM groups were treated with the original regimen designs without the necessity of reducing drug dosages when combined with the administration of rhG-CSF. The administration of rhG-CSF post both of the cytotoxic therapies brought about much higher rates of complete remission in both the groups (CHOP, 75 percent; ProMACE/CytaBOM, 75 percent), as compared with those of the previous study without the rhG-CSF administration. Regarding response rates according to the International prognostic factor index, the CHOP group showed a lower rate of complete remission in patients with risk factors, compared with ProMACE/CytaBOM group. This result suggested that the administration of rhG-CSF may offer one important approach for improving the first-line therapy for aggressive NHL with high risk factors.

• Authors: M Okabe, I Maekawa, S Suzuki, M Higuchi, M Morioka, K Nishi, T Itaya, T Ohmura, M Kawamura, N Fuzimoto
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 19 Issue 5-6 Pg. 485-91 (Nov 1995) ISSN: 1042-8194 [Print] United States
• PMID: 8590851 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Immunologic Factors
• Recombinant Proteins
• Cytarabine
• Bleomycin
• Granulocyte Colony-Stimulating Factor
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Leucovorin
• Prednisone
• Methotrexate

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Bleomycin (administration & dosage)
• Combined Modality Therapy
• Cyclophosphamide (administration & dosage)
• Cytarabine (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Granulocyte Colony-Stimulating Factor (therapeutic use)
• Humans
• Immunologic Factors (therapeutic use)
• Leucovorin (administration & dosage)
• Lymphoma, Non-Hodgkin (drug therapy, therapy)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Pilot Projects
• Prednisone (administration & dosage)
• Recombinant Proteins (therapeutic use)
• Remission Induction
• Vincristine (administration & dosage)